Brandon Potts v. The United States of America, et al.

CourtDistrict Court, D. South Carolina
DecidedJanuary 27, 2026
Docket2:25-cv-09579
StatusUnknown

This text of Brandon Potts v. The United States of America, et al. (Brandon Potts v. The United States of America, et al.) is published on Counsel Stack Legal Research, covering District Court, D. South Carolina primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Brandon Potts v. The United States of America, et al., (D.S.C. 2026).

Opinion

UNITED STATES DISTRICT COURT DISTRICT OF SOUTH CAROLINA CHARLESTON DIVISION

Brandon Potts, ) Case No. 2:25-cv-09579-JFA-MGB ) Plaintiff, ) ) v. ) ) REPORT AND RECOMMENDATION The United States of America, et al., ) ) Defendants. ) ___________________________________ )

Plaintiff Brandon Potts (“Potts”) brings this civil action alleging, inter alia, negligent medical care pursuant to the Federal Tort Claims Act (“FTCA”), 28 U.S.C. § 2671 et seq.1 This matter is before the Court upon a Motion to Dismiss filed by Defendant NaphCare, Inc. (“NaphCare”) (Dkt. No. 19); a Motion to Substitute filed by Defendant the United States of America (the “United States”) (Dkt. No. 23); and a Motion to Dismiss filed by Defendants the United States, Olusegun Taiwo, and Timothy Young (collectively, “Federal Defendants”) (Dkt. No. 24). For the reasons set forth herein, the undersigned recommends granting in part and denying in part NaphCare’s Motion to Dismiss; granting the United States’ Motion to Substitute, and granting the Federal Defendants’ Motion to Dismiss. BACKGROUND This action stems from events that occurred while Plaintiff was incarcerated and in the custody of the Federal Bureau of Prisons (“BOP”), specifically at the federal correctional facilities in Edgefield County, South Carolina (“FCI Edgefield”) and Atlanta, Georgia (“USP Atlanta”).2

1 Pursuant to the provisions of Title 28, United States Code, Section 636(b)(1) and Local Rule 73.02(B)(2), D.S.C., pretrial proceedings in this action have been referred to the assigned United States Magistrate Judge. 2 As discussed infra, Plaintiff was granted compassionate release from federal custody on August 22, 2024, pursuant to 18 U.S.C. § 3582(c)(1)(A). (Dkt. No. 15 at 2.) Defendant NaphCare is a corporation hired by the BOP as an independent contractor to provide healthcare services to BOP inmates, “which include physician and nursing services, pharmaceuticals, and administrative support.” (Dkt. No. 15 at 2.) Plaintiff alleges that “NaphCare’s contract with FCI Edgefield and USP Atlanta required that the [BOP] pay millions of dollars for

NaphCare’s services for calendar years 2022 and 2023. In return, NaphCare guaranteed that its services would comport with the standard of care.” (Id.) Plaintiff alleges that during the events at issue, Defendant Timothy Young, M.D. (“Young”) “was a physician who was providing healthcare services at FCI Edgefield” and Defendant Olusegun Taiwo, FNP-C (“Taiwo”) “was an advanced nurse care provider who was providing healthcare services at FCI Edgefield.” (Id. at 3.) According to Plaintiff, “[n]o later than June of 2022, Plaintiff presented to the healthcare providers at FCI-Edgefield with complaints associated with two black lesions on his skin that had increased in size over the past year.” (Id. at 4.) On August 9, 2022, Defendant Taiwo examined Plaintiff, “determined that Plaintiff needed to see an outside provider for a dermatology consultation,” and set “a target date of that appointment . . . for September 2022,” marking it “as

routine priority.” (Id.) Plaintiff alleges that “Defendant NaphCare and its employees, agents and representatives were responsible for coordinating with FCI-Edgefield for timely scheduling specialized healthcare, including dermatology consultations to outside providers.” (Id.) According to Plaintiff, Defendant NaphCare, the Federal Defendants, “John Doe, and Jane Doe failed to timely refer and/or schedule and/or arrange a dermatology consultation for Plaintiff, and he was note seen by an offsite dermatologist until on or about December 27, 2022.” (Id. at 5.) “At the December 27, 2022 appointment, a biopsy of the skin lesions was performed. Later that day, Plaintiff was transferred back to FCI Edgefield.” (Id.) Plaintiff’s “Clinical Encounter Note stated, ‘Inmate returned from a dermatology appt. Biopsy obtained to rule out melanoma per doctors note. Awaiting results. No further recommendation needed at this time.’” (Id.) Defendant Young reviewed and signed this Note “the following day.” (Id.) Plaintiff alleges that the biopsy results “indicated that Plaintiff likely had skin cancer,” and NaphCare “was in possession of those results.” (Id.) “[O]n January 6, 2023, and January 18, 2023, the outside dermatologist wrote to the

attention of the Defendants at FCI-Edgefield and stated that Plaintiff needs to be seen by a surgical oncologist ‘ASAP’ to check his lymph nodes and possibly begin chemotherapy treatment.” (Id.) Plaintiff alleges that “NaphCare was also in possession of this correspondence.” (Id.) According to Plaintiff, Defendant NaphCare, the Federal Defendants, “John Doe, and Jane Doe failed to inform Plaintiff of the results of his biopsy and the urgent recommendation of the dermatologist.” (Id.) In May 2023, while still unaware of his biopsy results, Plaintiff was transferred to USP Atlanta. (Id. at 6.) “On June 23, 2023, Plaintiff informed the healthcare providers at USP-Atlanta that he had continuing pain, and that he had never received the results from the December 2022 biopsy.” (Id.) Plaintiff was informed of his biopsy results on June 26, 2023 and he saw an

oncologist on June 26, 2023. (Id.) “On August 9, 2023, a positron emission tomography CT (“PET CT”) of the whole body found, ‘1. Intensely hypermetabolic skin lesion within the left anterior chest wall, consistent with known primary malignancy. 2. Hypermetabolic bilateral axillary lymph nodes are concerning for nodal metastatic disease.’” (Id.) “On October 3, 2023, an ultrasound- guided fine needle aspiration (“FNA”) of the left axillary lymph nodes revealed the presence of malignant cells, and Plaintiff was diagnosed with stage III metastatic malignant melanoma.” (Id.) Plaintiff alleges that “Defendants were [aware] of these results.” (Id.) Plaintiff alleges that “Defendant NaphCare and its employees, agents and representatives were responsible for coordinating with FCI-Edgefield and USP-Atlanta for timely scheduling specialized healthcare, including oncology and surgical consultations and treatment.” (Id.) According to Plaintiff, Defendant NaphCare, the Federal Defendants, “John Doe, and Jane Doe failed to timely refer and/or schedule and/or arrange a consultation for Plaintiff with a surgical oncologist and failed to timely ensure oncology treatment.” (Id.) Plaintiff alleges that “[b]ecause

of Defendants’ negligence, gross negligence, recklessness, carelessness, wantonness, and deviations from accepted medical standards, Plaintiff’s skin lesion metastasized and subsequently spread and grew for a considerable period of time, thereby requiring different and more extensive treatment(s) and worsening his prognosis.” (Id. at 7.) Plaintiff filed this action on August 1, 2025, and he filed the instant Amended Complaint on October 2, 2025. (Dkt. No. 15.) The Amended Complaint alleges three causes of action: (1) Medical Malpractice against “all Defendants”; (2) Negligence, Gross Negligence, Recklessness against Defendant NaphCare; and (3) “U.S. Constitutional Violations” under 42 U.S.C. § 1983 against Defendant NaphCare, the Federal Defendants, “John Doe, Jane Doe, ABC Inc., and XYZ Corp.” (Id. at 7–12.) The Amended Complaint also alleges an “Alternative” cause of action for

Wrongful Death against “all Defendants.” (Id. at 13.) On October 14, 2025, Defendant NaphCare filed a Motion to Dismiss. (Dkt. No. 19.) Plaintiff filed a response in opposition on October 27, 2025 (Dkt. No. 20), to which NaphCare filed a reply on November 3, 2025 (Dkt. No. 21).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Monell v. New York City Dept. of Social Servs.
436 U.S. 658 (Supreme Court, 1978)
Thomas v. Arn
474 U.S. 140 (Supreme Court, 1986)
Papasan v. Allain
478 U.S. 265 (Supreme Court, 1986)
New Hampshire v. Maine
532 U.S. 742 (Supreme Court, 2001)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Adams v. Bain
697 F.2d 1213 (Fourth Circuit, 1982)
United States v. Edward Lester Schronce, Jr.
727 F.2d 91 (Fourth Circuit, 1984)
John S. Clark Company v. Faggert & Frieden, P.C.
65 F.3d 26 (Fourth Circuit, 1995)
Lowery v. Stovall
92 F.3d 219 (Fourth Circuit, 1996)
Edwards v. City of Goldsboro
178 F.3d 231 (Fourth Circuit, 1999)
Giarratano v. Johnson
521 F.3d 298 (Fourth Circuit, 2008)
Andrew v. Clark
561 F.3d 261 (Fourth Circuit, 2009)
Nemet Chevrolet, Ltd. v. Consumeraffairs. Com, Inc.
591 F.3d 250 (Fourth Circuit, 2009)
Fuller v. Blanchard
595 S.E.2d 831 (Court of Appeals of South Carolina, 2004)
Roberts v. Hunter
426 S.E.2d 797 (Supreme Court of South Carolina, 1993)

Cite This Page — Counsel Stack

Bluebook (online)
Brandon Potts v. The United States of America, et al., Counsel Stack Legal Research, https://law.counselstack.com/opinion/brandon-potts-v-the-united-states-of-america-et-al-scd-2026.